Guidance
Evidence-based recommendations on the PROGENSA PCA3 assay and the Prostate Health Index (PHI) for use in people having investigations for suspected prostate cancer.
Guidance development process
How we develop NICE diagnostics guidance
Is this guidance up to date?
We reviewed the evidence in November 2018 and we are updating this guidance as part of an update of NICE’s prostate cancer guideline. See the guideline in development page for progress on the update.
Your responsibility
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.